Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

v3.8.0.1
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2017
Fair Value Disclosures [Abstract]  
Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial assets and liabilities measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:

 

    As of September 30, 2017     Fair Value Measurements  
    Carrying     Fair     As of September 30, 2017  
    Amount     Value     Level 1     Level 2     Level 3  
Assets:                                        
Cash and cash equivalents:                                        
Cash   $ 11,703     $ 11,703     $ 11,703     $             -     $ -  
    $ 11,703     $ 11,703     $ 11,703     $ -     $ -  
Liabilities:                                        
Contingent consideration:                                        
Asuragen   $ 1,407     $ 1,407     $ -     $ -     $ 1,407  
Other long-term liabilities:                                        
Warrant liability     733       733       -       -       733  
    $ 2,140     $ 2,140     $ -     $ -     $ 2,140  

  

 

    As of December 31, 2016     Fair Value Measurements  
    Carrying     Fair     As of December 31, 2016  
    Amount     Value     Level 1     Level 2     Level 3  
Assets:                                        
Cash and cash equivalents:                                        
Cash   $ 602     $ 602     $ 602     $ -     $ -  
    $ 602     $ 602     $ 602     $ -     $ -  
Liabilities:                                        
Contingent consideration:                                        
Asuragen   $ 1,545     $ 1,545     $ -     $ -     $ 1,545  
RedPath     5,969       5,969       -       -       5,969  
    $ 7,514     $ 7,514     $ -     $ -     $ 7,514  

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

A roll forward of the carrying value of the contingent consideration, embedded conversion option and warrant liabilities from December 31, 2016 to September 30, 2017 is as follows:

 

    December 31, 2016     Initial Liability     Payments     Accretion     Cancellation
of Obligation/
Conversions Exercises 		    Mark to Market     September 30, 2017  
Contingent consideration:                                                        
Asuragen   $ 1,545             $ (260 )   $ 122     $ -     $ -     $ 1,407  
Redpath     5,969               -       -       (5,969 )     -       -  
Embedded conversion option     -       208       -       -       (269 )     61       -  
Pre-Funded Warrants     -       2,247       -       -       (2,337 )     90       -  
Underwriters Warrants     -       422       -       -       -       311       733  
    $ 7,514     $ 2,877     $ (260 )   $ 122     $ (8,575 )   $ 462     $ 2,140